Search

Migration is the movement of people across a specified boundary for the purpose of establishing a new or semi-permanent residence. With up to 2% of the world’s population living outside of their country of birth, the potential impact of population mobility on health and use of health services of migrant host nations is increasing in its importance. Historically this movement was nomadic, often causing significant conflict with the indigenous population and their displacement or cultural assimilation. Qualitative method was used to this research. Present study draws on interviews, with 7 interviews with UPM student’s emigrants. Results illustrate immigrant status may impact family stress and uncertainty, health outcomes, and educational attainment and may result in increased social isolation for students in immigrant families.

Background and Objective: Oral candidiasis is a common opportunistic infection in diabetic patients. Candida albicans is colonized on different oral surfaces such as tongue, palate, dental caries and plaques. This study aimed to determine the prevalence of Candida albicans in the mouth of diabetic patient. Material and Methods: This cross - sectional study was conducted on 120 diabetic patients. After completing the questionnaire, the saliva samples were obtained and cultured on sabouraud agar medium containing 0.005% chloramphenicol. For final diagnosis, Germ tube test and Sugar absorption test (with API 120 kit) were used. Results: Of 120 patients, 61 (50.8%) were positive for Candida. Candida infection rate was relatively higher in older patients and in women. The rate was significant in the patients using dentures (P< 0.001) and the ones keeping on smoking (P

New formulations and technologies have been developed through oral drug delivery systems’ researches. Such researches display significance of oral route amongst patients. We’ve reviewed all the features associated with medicated chewing gum as a modern drug delivery by introducing the history, advantages and disadvantages, methods of manufacturing, composition differences, evaluation tests and examples of varieties of medicated chewing gums. Acceptance of medicated chewing gum has been augmented through years. The advantages and therapeutic benefits of chewing gum support its development as we can see new formulations with new drugs contained have been produced from past and are going to find a place in market by formulation of new medicated chewing gums. Potential applications of medicated chewing gums are highly widespread as they will be recognized in future. Nowadays standards for qualifying chewing gums are the same as tablets. Patient-centered studies include medicated chewing gums as a delivery system too which creates compliance for patients.

Background: There is no information about the pattern of use of earphones and music players in Iranian adolescents. The aim of this study was to assess the prevalence and pattern of the use of earphone and music player devices as a main risk factor for hearing loss in adolescents of Tabriz city, northwest of Iran. Methods : In this cross-sectional study in November 2011, 2,359 high school students were randomly selected and were asked to complete a 20-item questionnaire about the pattern of using earphones and music players. Results: The results showed that 44.3% [confidence interval (CI) 95%: 38.3-50.3] of the respondents had a history of hearing problems that was significantly different between males and females (42.2% of males and 47% of females, p: 0.02). Notably, 36.8% of the participants stated that they listened to music without any rest or stop. Almost 49.6% (CI 95%: 44.4-54.4) of the students reported listening to ′somewhat loud′ (gain setting at 50%) or ′very loud′ (gain setting more than 50%) volume level of music. In terms of the kind of earphones, 17.1% of the participants used headphones, 34.8% used earbud-style headphones, 32.3% used supra-aural headphones, and 15.8% of them did not use any type of earphones. Conclusions: Students have risky patterns of using earphones and music-listening devices. Planning educational programs in this domain for adolescents especially in high schools is necessary.

Source: ICHE Conference Archive - https://mdi-de.baw.de/icheArchive

Expression and secretion of inflammation markers are disturbed in obesity. Interleukin-6 reduces body fat mass. The common G-174C polymorphism in the promoter of IL-6 gene has been reported that effects on transcriptional regulation. The objective was to investigate association of the common polymorphism G-174C with obesity in Iranian population. The present study is cross sectional association study that included 242 individuals (110 men and 132 women). Serum IL-6 levels, C-reactive protein, fasting blood glucose and blood lipids profile were measured .BMI and WHR were calculated. Genotyping is carried out by PCR and RFLP. The frequencies of G and C allele were 64.5% and 35.5%, respectively. The G-174C polymorphism was not associated with BMI and WHR. However in obese individual, fasting blood glucose was significantly higher in carrier of C allele compared with the noncarrier. The IL-6 G-174C polymorphism is not a risk factor for obesity in Iranian population., {"references":["Hans Hauner, Symposium on ÔÇÿBiology of obesity-Secretory factors from\nhuman adipose tissue and their functional role, Proceedings of the\nNutrition Society , pp163-169, 2005.","Lu Qi, Cuilin Zhang, Rob M. van Dam and Frank B. Hu, Interleukin-6\nGenetic Variability and Adiposity: Associations in Two Prospective\nCohorts and Systematic Review in 26,944 Individuals, Journal of Clinical\nEndocrinology & Metabolism , 92: 93618-3625, 2007.","I Wernstedt, A-L Eriksson, A Berndtsson1, J Hoffstedt, S Skrtic, T Hedner,\nLM Hulte'n,O Wiklund, C Ohlsson and J-O Jansson , A common\npolymorphism in the interleukin-6 genepromoter is associated with\noverweight, International Journal of Obesity 28, pp 1272-1279, 2004.","Victoria Rotter Sopasakis, Madele'ne Sandqvist,Birgit Gustafson, Ann\nHammarstedt, Martin Schmelz, Xiaolin Yang, Per-Anders Jansson, and\nUlf Smith , High Local Concentrations and Effectson Differentiation\nImplicate Interleukin-6 as aParacrine Regulator, Obesity res. 12 :3(454-\n461), 2004.","Berthier MT, Paradis AM, Tchernof A, Bergeron J, Prud-homme D,\nDespres JP, Voh l, MC The interleukin 6-174G/C polymorphism is\nassociated with indices of obesity in men. J Hum Genet 48:14-19, 2003.","Klipstein-Grobusch K, Mohlig M, Spranger J, Hoffmann K, Rodrigues\nFU, Sharma AM, Klaus S, Pfeiffer AF, Boeing H, Interleukin-6 g.-\n174G>C promoter polymorphism is associated with obesity in the EPICPotsdam\nStudy. Obesity (Silver Spring) 14:14-18, 2006.","Lieb W, Pavlik R, Erdmann J, Mayer B, Holmer SR, Fischer M, Baessler\nA, Hengstenberg C, Loewel H, Doering A, Riegger GA, Schunkert H, No\nassociation of interleukin-6 gene polymorphism (-174 G/C) with\nmyocardial infarction or traditional cardiovascular risk factors. Int J\nCardiol 97:205-212, 2004.","Moffett SP, Zmuda JM, Cauley JA, Stone KL, Nevitt MC, Ensrud KE,\nHillier TA, Hochberg MC, Joslyn G, Morin P, Cummings, Association of\nthe G-174C variant in the interleukin-6 promoter region with bone loss\nand fracture risk in older women. J Bone Miner Res 19:1612-1618, 2004.","Wallenius V, Wallenius K, Ahre'n B, Rudling M, Carlsten H,Dickson SL,\nOhlsson C, Jansson J-O, Interleukin-6-deficient mice develop matureonset\nobesity. Nat Med 8: 75-79, 2002.\n[10] Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries\nS, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6)\ngene on IL-6 transcription and plasma IL-6levels, and an association with\nsystemic-onset juvenile chronicarthritis. J Clin Invest; 102: 1369-1376,\n1998.\n[11] Terry CF, Loukaci V, Green FR. Cooperative influence of genetic\npolymorphisms on interleukin 6 transcriptional regulation. J BiolChem;\n275:18138-18144, 2000.\n[12] Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U,Auffarth\nGU, Grau AJ, Green FR, Grond-Ginsbach C, SchwaningerM. Multiple\nlevels of regulation of the interleukin-6 system in stroke. Stroke; 34:\n1864-1869, 2003.\n[13] Kazumi T, Kawaguchi A, Hirano T, Yoshino G. C-reactive protein in\nyoung, apparently healthy men: associations with serumleptin, QTc\ninterval, and high-density lipoprotein-cholesterol.Metabolism, 52: 1113-\n1116,2003.\n[14] Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I,\nLaakso M. The C-174G promoter polymorphism of the IL-6 gene affects\nenergy expenditure and insulin sensitivity. Diabetes,52: 558-561,2003.\n[15] Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A,\nLowe GD, Humphries SE. Interleukin-6 gene -174g4c and -572g4c\npromoter polymorphisms are strong predictors of plasma interleukin-6\nlevels after coronary artery bypass surgery. Arterioscler Thromb Vasc\nBiol; 21: 1458-1463, 2001.\n[16] Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Roodell\nMM, Weatherbee JA, Young MR, Nenchausky BM,Scheving LE.\nCircadian characteristics of circulating interleukin-6 in men. J Allergy\nClin Immunol; 95: 1029-1035, 1995.\n[17] Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, Jebb\nSA, Lip GY, O-Rahilly S. Partial leptin deficiency and human adiposity.\nNature; 414: 34-35, 2001.\n[18] Flier JS. Obesity wars: molecular progress confronts an\nexpandingepidemic. Cell 2004; 116: 337-350.\n[19] Wallenius K, Wallenius VW, Sunter D, Dickson SL, Jansson J-O.\nIntracerebroventricular interleukin-6 treatment decreases bodyfat in rats.\nBiochem Biophys Res Comm; 293: 560-565, 2002.\n[20] Rothwell NJ, Busbridge NJ, Lefeuvre RA, Hardwick AJ, Gauldie J,\nHopkins SJ. Interleukin-6 is a centrally acting endogenous pyrogen in the\nrat. Can J Physiol Pharmacol;69: 1465-1469, 1991.\n[21] Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson\nJO. Interleukin-6 levels in the central nervous system are negatively\ncorrelated with fat mass in overweight/obese subjects. J Clin Endocrinol\nMetab; 88: 4379-4383, 2003.\n[22] Fernandez-Real JM, Ricart W. Insulin resistance and chronic\ncardiovascular inflammatory syndrome. Endocr Rev; 24: 278-301, 2003.\n[23] Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS,Chrousos\nGP. Dose-dependent effects of recombinant human interleukin-6 on\nglucose regulation. J Clin Endocrinol Metab;82: 4167-4170, 1997.\n[24] Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ,\nVeenhof CH, Sauerwein HP, Endocrinologic and metabolic effects of\ninterleukin-6 in humans. Am J Physiol; 268: E813-E819, 1995.\n[25] Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in\nhuman splanchnic and adipose tissue. J Physiol; 543: 379-386, 2002.\n[26] Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P,\nvan Hall G, Febbraio MA, Pedersen BK. Acute interleukin-6\nadministration does not impair muscle glucose uptake or whole-body\nglucose disposal in healthy humans. J Physiol; 548: 631-638, 2003.\n[27] Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, SatoB, Imai\nN, Suemura M, Kakehi T, Takagi N, Kishimoto T. Toxicity,\npharmacokinetics, and dose-finding study of repetitive treatment with the\nhumanized anti-interleukin 6 receptor antibody MRA in rheumatoid\narthritis. Phase I/II clinical study. J Rheumatol; 30: 1426-1435, 2003."]}

Objective: Mutation in KRAS gene is one of the most common genetic changes among patients with colorectal cancer (CRC), which is observed in 30-45% of cases. This study aims to estimate the prevalence of this mutation among patients with primary or metastatic CRC. Patients and Methods: Eligible studies were identified during a comprehensive electronic search, applying inclusion/exclusion criteria and quality assessment. Stata version 11 software was used for data analysis. The heterogeneity between the results of the primary studies was assessed using Cochrane and I-square indices. Random effect model was applied for combining the primary estimates. Point and pooled estimates (with 95% confidence intervals) were presented by forest plots. Investigating the factors associated with heterogeneity was carried out using meta-regression models. The publication bias was traced by Egger test. Results: Combining the results of 164 eligible studies, the total prevalence of KRAS gene mutation among primary tumor samples was estimated as of 33.14% (95% confidence interval: 30.08- 36.20). The corresponding figure for metastatic cancer was estimated as of 36.20 % (95% confidence interval: 33.96- 38.44). Prevalence of this mutation among patients with primary CRC in EMRO, EURO, PAHO, SEARO and WAPRO was 30.23%, 35.12%, 31.83%, 33.17% and 32.64%, respectively. Corresponding rates for mutation among metastatic cases were 42.20%, 38.46%, 36.06%, 42.80%, 33.05%, respectively. In addition, the total prevalence of KRAS gene mutation in codons 12 and 13 was estimated as 76.69% and 28.49%, respectively. Conclusions: More than one-third of patients with CRC carried KRAS gene mutation particularly in the metastatic tumors. The rate of mutation was the same in different WHO regions.